skip to main content

The FDA and 23andMe

Discover how 23andMe raw results are shaping the debate on medical services versus genealogical services amidst shifting consumer demands.

Written byRazib Khan
| 1 min read
Follow on GoogleGoogle News Preferred Source
Placeholder image

Newsletter

Sign up for our email newsletter for the latest science news

Sign Up

Placeholder image showing Earth from space with an alert icon and the message ‘This image is no longer available.’

First, download your 23andMe raw results now if you have them. If you don't know what's going on, the FDA has finally started to move aggressively against the firm. Unfortunately this is not surprising, as this was foreshadowed years ago. And, 23andMe has been moving aggressively to emphasize its medical, as opposed to genealogical, services over the past year. But this isn't the story of one firm. This is the story of government response to very important structural shifts occurring in the medical delivery system of the United States. The government could potentially bankrupt 23andMe, but taking a step back that would still be like the RIAA managing to take down Napster. The information is coming, and if there's one thing that can overpower state planning it is consumer demand. Unless the US government wants to ban their citizens from receiving their own genetic data they're just putting off the inevitable outsourcing of various interpretation services. Engagement would probably be the better long term bet, but I don't see that happening.

Meet the Author

Related Topics

Stay Curious

JoinOur List

Sign up for our weekly science updates

View our Privacy Policy

SubscribeTo The Magazine

Save up to 40% off the cover price when you subscribe to Discover magazine.

Subscribe